Sepsis survival: risks, realities and challenges
Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation that damages its tissues …
Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation that damages its tissues …
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) …
A Phase I trial of Replicate Bioscience’s self-replicating RNA-based vaccine for rabies has elicited an immune response against a disease …
Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised …
The 43rd Annual JP Morgan Healthcare Conference took place in San Francisco, California on January 13–16, 2025. This annual conference is …
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company …
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 receptor (MC4R) bremelanotide with …
AI has frequently been in the headlines recently due to its potentially transformative capabilities — and the technology is making …
The US Military’s Defence Health Agency (DHA) has partnered with the Global Coalition for Adaptive Research (GCAR) for a platform …
MSD has commenced the Phase III waveLINE-010 trial to assess its investigational antibody-drug conjugate (ADC), zilovertamab vedotin, combined with rituximab …
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential …
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III …
Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the …
All nine patients in a Phase I investigator-led trial of a personalised kidney cancer vaccine have successfully generated anti-cancer immune …
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine …